Your browser doesn't support javascript.
loading
Symptomatic vs. non-symptomatic device-related thrombus after LAAC: a sub-analysis from the multicenter EUROC-DRT registry.
Vij, Vivian; Cruz-González, Ignacio; Galea, Roberto; Piayda, Kerstin; Nelles, Dominik; Vogt, Lara; Gloekler, Steffen; Fürholz, Monika; Meier, Bernhard; Räber, Lorenz; O'Hara, Gilles; Arzamendi, Dabit; Agudelo, Victor; Asmarats, Lluis; Freixa, Xavier; Flores-Umanzor, Eduardo; De Backer, Ole; Sondergaard, Lars; Nombela-Franco, Luis; McInerney, Angela; Salinas, Pablo; Korsholm, Kasper; Nielsen-Kudsk, Jens Erik; Afzal, Shazia; Zeus, Tobias; Operhalski, Felix; Schmidt, Boris; Montalescot, Gilles; Guedeney, Paul; Iriart, Xavier; Miton, Noelie; Saw, Jacqueline; Gilhofer, Thomas; Fauchier, Laurent; Veliqi, Egzon; Meincke, Felix; Petri, Nils; Nordbeck, Peter; Gonzalez-Ferreiro, Rocio; Bhatt, Deepak L; Laricchia, Alessandra; Mangieri, Antonio; Omran, Heyder; Schrickel, Jan Wilko; Rodes-Cabau, Josep; Nickenig, Georg; Sievert, Horst; Sedaghat, Alexander.
Afiliação
  • Vij V; Department of Cardiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
  • Cruz-González I; University Hospital of Salamanca, CIBER CV, IBSAL, Salamanca, Spain.
  • Galea R; University Hospital Bern, Bern, Switzerland.
  • Piayda K; CardioVasculäres Centrum, Frankfurt, Germany.
  • Nelles D; Department of Cardiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
  • Vogt L; Department of Cardiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
  • Gloekler S; University Hospital Bern, Bern, Switzerland.
  • Fürholz M; University Hospital Bern, Bern, Switzerland.
  • Meier B; University Hospital Bern, Bern, Switzerland.
  • Räber L; University Hospital Bern, Bern, Switzerland.
  • O'Hara G; Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.
  • Arzamendi D; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Agudelo V; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Asmarats L; Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.
  • Freixa X; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Flores-Umanzor E; Hospital Clinic Barcelona, Barcelona, Spain.
  • De Backer O; Hospital Clinic Barcelona, Barcelona, Spain.
  • Sondergaard L; Rigshospitalet, University Hospital Copenhagen, Copenhagen, Denmark.
  • Nombela-Franco L; Rigshospitalet, University Hospital Copenhagen, Copenhagen, Denmark.
  • McInerney A; Hospital Clinico San Carlos Madrid, Madrid, Spain.
  • Salinas P; Hospital Clinico San Carlos Madrid, Madrid, Spain.
  • Korsholm K; Hospital Clinico San Carlos Madrid, Madrid, Spain.
  • Nielsen-Kudsk JE; Aarhus University Hospital, Aarhus, Denmark.
  • Afzal S; Aarhus University Hospital, Aarhus, Denmark.
  • Zeus T; University Hospital Düsseldorf, Düsseldorf, Germany.
  • Operhalski F; University Hospital Düsseldorf, Düsseldorf, Germany.
  • Schmidt B; Agaplesion Bethanien Krankenhaus, CBB, Frankfurt, Germany.
  • Montalescot G; Agaplesion Bethanien Krankenhaus, CBB, Frankfurt, Germany.
  • Guedeney P; ACTION Study Group, Pitié-Salpêtrière Hospital (AP-HP), Sorbonne University, Paris, France.
  • Iriart X; ACTION Study Group, Pitié-Salpêtrière Hospital (AP-HP), Sorbonne University, Paris, France.
  • Miton N; University Hospital Bordeaux, Bordeaux, France.
  • Saw J; University Hospital Bordeaux, Bordeaux, France.
  • Gilhofer T; Vancouver General Hospital, Vancouver, Canada.
  • Fauchier L; University Hospital Zurich, Zurich, Switzerland.
  • Veliqi E; University Hospital Tours, Tours, France.
  • Meincke F; St. Georg Hospital Hamburg, Hamburg, Germany.
  • Petri N; St. Georg Hospital Hamburg, Hamburg, Germany.
  • Nordbeck P; University Hospital Würzburg, Würzburg, Germany.
  • Gonzalez-Ferreiro R; University Hospital Würzburg, Würzburg, Germany.
  • Bhatt DL; University Hospital of Salamanca, CIBER CV, IBSAL, Salamanca, Spain.
  • Laricchia A; Mount Sinai Heart, Mount Sinai Hospital, New York, USA.
  • Mangieri A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
  • Omran H; Humanitas Research Hospital IRCCS, Rozzano, Italy.
  • Schrickel JW; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
  • Rodes-Cabau J; Humanitas Research Hospital IRCCS, Rozzano, Italy.
  • Nickenig G; Marienkrankenhaus, Bonn, Germany.
  • Sievert H; Department of Cardiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
  • Sedaghat A; Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.
Clin Res Cardiol ; 112(12): 1790-1799, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37294311
ABSTRACT

BACKGROUND:

Device-related thrombus (DRT) after left atrial appendage closure (LAAC) is associated with adverse outcomes, i.e. ischemic stroke or systemic embolism (SE). Data on predictors of stroke/SE in the context of DRT are limited.

AIMS:

This study aimed to identify predisposing factors for stroke/SE in DRT patients. In addition, the temporal connection of stroke/SE to DRT diagnosis was analyzed.

METHODS:

The EUROC-DRT registry included 176 patients, in whom DRT after LAAC were diagnosed. Patients with symptomatic DRT, defined as stroke/SE in the context of DRT diagnosis, were compared against patients with non-symptomatic DRT. Baseline characteristics, anti-thrombotic regimens, device position, and timing of stroke/SE were compared.

RESULTS:

Stroke/SE occurred in 25/176 (14.2%) patients diagnosed with DRT (symptomatic DRT). Stroke/SE occurred after a median of 198 days (IQR 37-558) after LAAC. In 45.8% stroke/SE occurred within one month before/after DRT diagnosis (DRT-related stroke). Patients with symptomatic DRT had lower left ventricular ejection fractions (50.0 ± 9.1% vs. 54.2 ± 11.0%, p = 0.03) and higher rates of non-paroxysmal atrial fibrillation (84.0% vs. 64.9%, p = 0.06). Other baseline parameters and device positions were not different. Most ischemic events occurred among patients with single antiplatelet therapy (50%), however, stroke/SE was also observed under dual antiplatelet therapy (25%) or oral anticoagulation (20%).

CONCLUSION:

Stroke/SE are documented in 14.2% and occur both in close temporal relation to the DRT finding and chronologically independently therefrom. Identification of risk factors remains cumbersome, putting all DRT patients at substantial risk for stroke/SE. Further studies are necessary to minimize the risk of DRT and ischemic events.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Trombose / Apêndice Atrial / Acidente Vascular Cerebral Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Res Cardiol Assunto da revista: CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Trombose / Apêndice Atrial / Acidente Vascular Cerebral Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Res Cardiol Assunto da revista: CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
...